Application of genetically engineered bacterium VNP20009-M to preparation of medicine for treating sarcomas

A technology of VNP20009-M, genetically engineered bacteria, applied in gene therapy, microbial-based methods, anti-tumor drugs, etc., can solve the problem of no anti-tumor effect observed

Pending Publication Date: 2017-09-01
GUANGZHOU SINOGEN PHARMA CO LTD
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Two phase I clinical studies conducted in the United States have shown that it

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of genetically engineered bacterium VNP20009-M to preparation of medicine for treating sarcomas
  • Application of genetically engineered bacterium VNP20009-M to preparation of medicine for treating sarcomas
  • Application of genetically engineered bacterium VNP20009-M to preparation of medicine for treating sarcomas

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] The construction of embodiment 1 genetically engineered bacteria VNP20009-M

[0034] The construction method and process of the genetically engineered bacteria VNP20009-M of the present invention are as described in the examples of Chinese patent CN105983103A.

[0035] (1) Construction of a plasmid expressing the L-methioninase gene.

[0036] Synthesized L-methioninase (GenBank: L43133.1) gene was subcloned into pUC57 plasmid (GenScript), and then subcloned into pSVSPORT plasmid (invitrogen) through Kpn I and Hind III restriction sites to obtain pSVSPORT-L- methioninase expression plasmid. The specific construction process is as follows:

[0037] Digest the pSVSPORT plasmid with Kpn I and Hind III. The digestion system is: 2 μg plasmid DNA, 3 μL 10×buffer, 1.5 μL Kpn I enzyme, 1.5 μL Hind III enzyme, add ddH2O to make up the volume to 30 μL, and incubate at 37°C for 3 hours . Then the digestion system was separated by electrophoresis in 1% agarose gel, the DNA band ...

Embodiment 2

[0048] Example 2 Effect of genetically engineered bacteria VNP20009-M in treating soft tissue sarcoma

[0049] 1) Past medical history and diagnosis

[0050] A male patient, 64 years old, had a mass in his left leg that was identified as spindle cell sarcoma by needle biopsy at Nanjing Drum Tower Hospital. After tumor resection, the tissue was taken again for pathological analysis, showing tumor cells SMA(-), DES(-), MyoD1(-), FN(+), STAT6(-), CD34(-), S100(-), CKpan (-), EMA (-), Vimentin (++), combined with HE section, consistent with malignant fibrous histiocytoma.

[0051] Periodic follow-up and re-examination of CT revealed a soft tissue mass in the upper lobe of the right lung, and biopsy pathology showed spindle cell sarcoma. Based on the patient's previous treatment and related examinations, a diagnosis of postoperative recurrence of spindle cell sarcoma with lung metastasis was made.

[0052] 2) Treatment plan

[0053] Genetically engineered bacteria VNP20009-M di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of genetically engineered drugs and particularly relates to new application of a genetically engineered bacterium VNP20009-M to preparation of a medicine for treating sarcomas. On the current basis, the genetically engineered bacterium VNP20009-M is used for treating the sarcomas, can effectively kill tumor cells to eliminate tumor lesions, and the genetically engineered bacterium has no obvious toxic or side effects on a human body, and therefore, provides a safe and effective new way for treating the sarcomas.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering drugs, and in particular relates to a new application of genetic engineering bacteria VNP20009-M in the preparation of drugs for the prevention and treatment of malignant sarcoma. Background technique [0002] Cancer has become an important cause of human death, and the incidence of cancer increased by 33% between 2005 and 2015. The "Global Cancer Report 2014" published by the World Health Organization (WHO) predicts that global cancer cases will show a rapid growth trend, from 14 million in 2012 to 19 million in 2025, and will reach 24 million in 2035 . [0003] Sarcoma is a malignant tumor derived from mesenchymal tissue (including connective tissue and muscle), which mostly occurs in fat, fascia, muscle, fiber, lymphatic and blood vessels, periosteum and both ends of long bones. Each type of sarcoma has different histological and biological characteristics and different tendency o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K38/51A61K35/74A61P35/00A61P35/04
CPCA61K38/51A61K48/005A61K35/74A61K2300/00C12N9/88A61P35/00A61P35/04Y02A50/30C12N15/74C12N1/20C12Y404/01011A61K9/0019C12N1/205C12R2001/42
Inventor 赵子建林艳周素瑾李芳红
Owner GUANGZHOU SINOGEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products